Mr. Robert Farrell reports
CLARITAS ANNOUNCES GRANT OF STOCK OPTIONS TO DIRECTORS AND OFFICERS
Claritas Pharmaceuticals Inc. has granted stock options on July 23, 2021, to the directors and officers of the company. The stock options have an exercise price of 51 cents per common share and expire 10 years from the date of grant. One-third of the options granted vested on July 23, 2021, and the remaining options will vest in 24 equal monthly instalments commencing August, 2021.
Stock options to purchase 50,000 common shares of the company were granted to Prof. Salvatore Cuzzocrea, an independent member of the company's board of directors; stock options to purchase 50,000 common shares of the company were granted to Perenlei Enkhbaatar, MD, an independent member of the company's board of directors; stock options to purchase 155,098 common shares of the company were granted to Victoria Rudman, the company's chief financial officer; and stock options to purchase 1,768,792 common shares of the company were granted to Robert Farrell, JD, the company's chairman, president and CEO.
About Claritas Pharmaceuticals Inc.
Claritas Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for patients with significant unmet medical needs. Claritas focuses on areas of unmet medical need, and leverages its expertise to find solutions that will improve health outcomes and dramatically improve people's lives.
We seek Safe Harbor.
© 2021 Canjex Publishing Ltd. All rights reserved.